<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03484507</url>
  </required_header>
  <id_info>
    <org_study_id>UCSF-IRB-17-23895</org_study_id>
    <nct_id>NCT03484507</nct_id>
  </id_info>
  <brief_title>Parasitic Ulcer Treatment Trial Pilot</brief_title>
  <official_title>Parasitic Ulcer Treatment Trial Pilot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Francis I. Proctor Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research to Prevent Blindness</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Francis I. Proctor Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of optimal treatments for acanthamoeba keratitis. In the first part of the
      study, participants will be randomized to chlorhexidine monotherapy or chlorhexidine plus
      povidone iodine. After four weeks of therapy, participants will be re-randomized to early
      corticosteroids, later corticosteroids, or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acanthamoeba keratitis is a rare eye infection that is difficult to treat. The mainstay of
      therapy is a biguanide agent such as chlorhexidine, though recent studies have found povidone
      iodine to be effective for killing acanthamoeba organisms in vitro. Thus, we randomize
      participants to topical chlorhexidine 0.04% monotherapy (i.e., routine care) versus topical
      chlorhexidine 0.04% plus topical poviodine iodine 2.5%. The primary outcome is clearance of
      acanthamoeba from the ocular surface at 4 weeks.

      The role of topical corticosteroids in acanthamoeba keratitis is controversial. Topical
      corticosteroids can promote growth of acanthamoeba, but may also reduce inflammation and
      vision-threatening complications of infection. Here, we randomize participants who have
      completed a course of anti-amoebic therapy to one of three groups: early prednisolone sodium
      phosphate 1% (started at 4 weeks), late prednisolone sodium phosphate 1% (started at 6 weeks)
      or placebo (started at 4 weeks). The primary outcome will be visual acuity at 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trial 1: Microbial clearance</measure>
    <time_frame>4 weeks</time_frame>
    <description>Summary score of smear, culture, PCR, and confocal microscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trial 2: Best spectacle corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trial 1: Best spectacle corrected visual acuity</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trial 1: Time to re-epithelialization</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trial 1: Clinical cure</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trial 2: Time to clinical cure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Acanthamoeba Keratitis</condition>
  <arm_group>
    <arm_group_label>Chlorhexidine monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical chlorhexidine 0.04%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorhexidine plus povidone iodine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical chlorhexidine 0.04% plus povidone iodine 2.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early corticosteroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical prednisolone sodium phosophate 1% for weeks 4-11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late corticosteroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artificial tears for weeks 4-5, then topical prednisolone sodium phosophate 1% for weeks 6-11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Artificial tears for weeks 4-11</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine</intervention_name>
    <description>1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit</description>
    <arm_group_label>Chlorhexidine monotherapy</arm_group_label>
    <arm_group_label>Chlorhexidine plus povidone iodine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Povidone-Iodine</intervention_name>
    <description>1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit</description>
    <arm_group_label>Chlorhexidine plus povidone iodine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Sodium Phosphate</intervention_name>
    <description>1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11</description>
    <arm_group_label>Early corticosteroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxypropyl Methylcellulose</intervention_name>
    <description>1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Sodium Phosphate</intervention_name>
    <description>1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11</description>
    <arm_group_label>Late corticosteroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxypropyl Methylcellulose</intervention_name>
    <description>1 drop 4 times daily for weeks 4-5</description>
    <arm_group_label>Late corticosteroids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Trial 1 Inclusion Criteria:

          -  Smear or culture positive for acanthamoeba

          -  Age 13 years or greater

        Trial 1 Exclusion Criteria:

          -  Interstitial or viral keratitis on history or examination

          -  Corneal perforation

          -  Therapeutic keratoplasty for acanthamoeba keratitis

          -  Unwillingness or inability to follow-up (e.g., living too far from hospital)

        Trial 2 Inclusion Criteria

          -  Smear or culture positive for acanthamoeba, with 4 weeks of anti-amoebic treatment

          -  Age 13 years or greater

          -  Willing to participate in study

        Trial 2 Exclusion Criteria

          -  Interstitial or viral keratitis on history or examination

          -  Fungus identified on culture and smear after 2 weeks of anti-amoebic treatment

          -  Corneal perforation

          -  Therapeutic keratoplasty for acanthamoeba keratitis

          -  Unwillingness or inability to follow-up (e.g., living too far from hospital)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy D Keenan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeremy D Keenan, MD</last_name>
    <phone>415-476-1442</phone>
    <email>jeremy.keenan@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caitlin Moe, MPH</last_name>
    <phone>415-502-2665</phone>
    <email>caitlin.moe@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aravind Eye Hospital</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Revathi Rajaraman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Hospital</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arun Panigrahi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2018</study_first_submitted>
  <study_first_submitted_qc>March 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <last_update_submitted>March 24, 2018</last_update_submitted>
  <last_update_submitted_qc>March 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Francis I. Proctor Foundation</investigator_affiliation>
    <investigator_full_name>Jeremy Keenan</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratitis</mesh_term>
    <mesh_term>Acanthamoeba Keratitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

